Recent progress in the field of energy homeostasis was triggered by the discovery of adipocyte hormone leptin and revealed a complex regulatory neuroendocrine network. A late addition is the novel stomach hormone ghrelin, which is an endogenous agonist at the growth hormone secretagogne receptor and is the motilin-related family of regulatory peptides. In addition to its ability to stimulate GH secretion and gastric motility, ghrelin stimulates appetite and induces a positive energy balance leading to body weight gain. With the discovery of the anorexigenic (appetiteinhibiting) and adipostatic hormone leptin, studies focused on defining neural circuits responsible for mediating leptin actions in the brain (1-13). The hypothalamus is the center for the integration of feeding and associated autonomic, neuroendocrine, and gastrointestinal activities. Ghrelin, identified as an endogenous ligand for the growth hormone secretagogue (GHS) receptor (14), functions as an orexigenic (appetite-stimulating) signal from the stomach when an increase in metabolic efficiency is necessary (15-17). Ghrelin regulates, in an antagonistic manner to leptin, synthesis and secretion of several neuropeptides in the hypothalamus that regulate feeding and associated hypothalamic functions. Here, we review the evidence indicating ghrelin as a crucial missing link between the stomach and the hypothalamus, and the clinical implication of this ghrelin/GHS receptor system in the control of gastrointestinal function, energy balance and growth.
With the discovery of the anorexigenic (appetiteinhibiting) and adipostatic hormone leptin, studies focused on defining neural circuits responsible for mediating leptin actions in the brain (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . The hypothalamus is the center for the integration of feeding and associated autonomic, neuroendocrine, and gastrointestinal activities. Ghrelin, identified as an endogenous ligand for the growth hormone secretagogue (GHS) receptor (14) , functions as an orexigenic (appetite-stimulating) signal from the stomach when an increase in metabolic efficiency is necessary (15) (16) (17) . Ghrelin regulates, in an antagonistic manner to leptin, synthesis and secretion of several neuropeptides in the hypothalamus that regulate feeding and associated hypothalamic functions. Here, we review the evidence indicating ghrelin as a crucial missing link between the stomach and the hypothalamus, and the clinical implication of this ghrelin/GHS receptor system in the control of gastrointestinal function, energy balance and growth.
GROWTH HORMONE SECRETAGOGUES (GHSs)
The pulsatile release of growth hormone (GH) from the anterior pituitary gland is regulated by tight interplay between the hypothalamic growth hormone-releasing hormone (GHRH) and somatostatin (18, 19) . GHRH stimulates GH synthesis and release whereas somatostatin inhibits the release. However, several other neurotransmitters and neuropeptides are assumed to play a role in the control of GH secretion.
In the past two decades, particular attention has been given to a new family of substances, named GH secretagogues (GHSs), which show a powerful GH-releasing effect. GHSs are non-natural, synthetic compounds developed by Bowers and co-workers that directly stimulate GH secretion (20 -22) (Fig. 1) . The prototype GH-releasing peptide 6 (GHRP-6) has been used as a diagnostic tool since before the isolation of GHRH in 1982 (23) . Orally active GHSs have been proposed as an alternative to GH, insulin-like growth factor I (IGF-I) and GHRH as a growth-promoting treatment in GHdeficient children, as well as an anabolic treatment in elderly patients with somatopause (19, 24 -26) .
GHSs act through specific G-protein-coupled recep-tor(s) (27, 28) distinct from that of GHRH and exert a powerful synergism when administered in addition to GHRH. The GHS receptor type Ia (GHS-RIa) transduces the GH-releasing effect of GHSs, whereas GHSRIb is a nonspliced, nonfunctional receptor mRNA variant. GHS-RIa operates through activation of the phospholipase-IP3 pathway and inhibition of K ϩ channels, leading to a rise in intracellular Ca 2ϩ . GHS-RIa is predominantly expressed in the pituitary and hypothalamus and at low levels in other brain regions such as ventral tegmental area, substantia nigra, nucleus tractus solitarius, and hippocampus as well as peripheral tissues such as heart, lung, pancreas, intestine, kidney, and adipose tissue (27) (28) (29) (30) (31) . It has been speculated that GHSs mimic an as yet unidentified endogenous hormone reflecting the presence of an additional neuroendocrine system regulating pulsatile GH secretion (32) (33) (34) .
GHRELIN IS AN ENDOGENOUS GHS AND MOTILIN-RELATED OREXIGENIC SIGNAL FROM THE STOMACH
Recently, Kojima and Kangawa identified the 28 amino acid peptide ghrelin as an endogenous ligand for the "orphan" GHS receptor (14, 35) . Ghre is the proto-IndoEuropean root of the word growth. Although most people assumed that the greatest concentrations would be in the hypothalamus, the highest GHS receptor activation was found in stomach extracts (14) . Indeed, Tomassetto and co-workers identified it separately from the stomach as the motilin-related peptide (36) , with structural and effect-related similarities to the duodenal hormone motilin that has a key role in the regulation of gastrointestinal motility (16, 17, 37) (Fig. 1) . Motilin was also known to have a GH-releasing effect (38) . Based on structural and effect-related similarities, motilin and ghrelin are considered to represent a novel gastrointestinal hormone family in addition to gastrin, secretin, pancreatic polypeptide (PP), insulin, epidermal growth factor (EGF), and tachykinin families (17, 39, 40) .
Two molecular forms of ghrelin are found in the stomach: the 28 amino acid ghrelin having n-octanoylated serine in position 3 and the 27 amino acid des-[Gln 14 )] ghrelin produced by alternative splicing of the ghrelin gene (14, 41) . The acylation appears to be essential for GH-releasing activity in both natural forms of ghrelin although des-acyl ghrelin may have some biological activities such as those acting as a survival 14 ] ghrelin is produced from the alternative splicing of the peptide coding region. Ghrelin does not have a carboxyl-terminal amide group, but its acylation is required for activation of growth hormone secretagogue (GHS) receptor-1a, a G-protein-coupled receptor. Ghrelin and its receptor are highly conserved across species. Human ghrelin and motilin show 36% identity in amino acid residues. Similarly, the human ghrelin receptor (GHS receptor1a) shows a remarkable 52% identity with the human motilin receptor (type 1a). Ghrelin and motilin thus represent a novel family of gastrointestinal hormones. MK-0677, CP-424,391, and NNC 26-0703 are examples of nonpeptidyl GHSs, which have been evaluated in long-term controlled clinical studies to assess their potential benefits in a variety of disease states such as idiopathic GH deficiency and catabolic states.
factor on the cardiovascular system (42) . Other minor forms of ghrelin are present in human plasma and stomach, measured as the total immunoreactivity by the conventional radioimmunoassay based on the carboxylterminal fragment of ghrelin (43) . Studies of structure activity show that amino-terminal fragments conserving the first five amino acids of the molecule display full functional activity (44) .
It is known that structural heterogeneity among species can be of major importance for motilin (45) . Five or more positions in the 22 amino acid structure of motilin may differ among mammalian species. The situation is more complex in rats in which motilin is not identified and exogenous motilin administration does not reproduce the gastrointestinal motor effect of the peptide. However, structural heterogeneity of ghrelin appears minor (46) , and human ghrelin is identical to rat ghrelin except for two residues (14) (Fig. 1) .
Ghrelin is expressed mainly in the stomach, by neuroendocrine cells (X/A-like cells in rodents and P/D1 cells in humans) in the fundus, and is secreted into the circulation (47) (48) (49) (50) . This is supported by the finding that gastrectomy reduces plasma ghrelin concentrations by 65% (51) . Gastric ghrelin cells show distinctive morphology and hormone reactivity with respect to histamine enterochromaffin-like, somatostatin D, glucagon A, or serotonin enterochromaffin cells (50) . Both open-and closed-type cells exist in the stomach (52), suggesting they receive both luminal and neuroendocrine information. Lower levels of ghrelin are found in the small and large intestine, pituitary gland (53), ␣ (54), ␤ (55), or novel (56) cells of the pancreatic islet, and neurons of the arcuate nucleus (ARC) in the basal hypothalamus (14) . Ghrelin has also been detected in kidney (57) , testis (58) , placenta (59) , and immune cells (29) . Like motilin, plasma ghrelin concentrations rise progressively during fasting and fall to a nadir within an hour of refeeding.
Gastric ghrelin production is regulated by nutritional and hormonal factors (17, 49, 60, 61) . Inhibitory signals seem to include somatostatin, interleukin 1␤ (IL-1␤), growth hormone itself, high-fat diet, and vagal tone, whereas fasting and a low-protein diet lead to increased expression and plasma concentrations of ghrelin. Regulation of circulating ghrelin during fasting and feeding may involve distinct mechanisms and pathways. The finding that GH lowers ghrelin expression suggests a feedback loop between stomach ghrelin and pituitary GH (49) , although systemic ghrelin concentrations appear not to be decreased in human acromegaly despite high GH concentrations (62) . The effects of leptin on ghrelin production are variably reported, i.e., increase, no change, or decrease, which might depend on the dosage or period of leptin administration and feeding conditions of the animals (49, 63, 64) . The latter may be important since increased ghrelin expression is observed after high-fat feeding for a short period that is evident only in the fasting condition (65) . No direct involvement of insulin or glucose is demonstrated in healthy humans at physiological concentrations (66) . The increased secretion of stomach ghrelin with fasting is unique when contrasted to a majority of gut hormones whose secretion increases with food intake and decreases with fasting.
Despite recent growth in our understanding of peripheral signals to hypothalamic pathways, ghrelin adds a new dimension to the interplay since it is the first gut peptide proved to have orexigenic properties (15, 17) . Although motilin can stimulate food intake after central administration, it produces the least effect when administered peripherally (67) (68) (69) . Almost all other gut peptides such as cholecystokinin (CCK) (70 -72) , glucagon-like peptide-1 (GLP-1) (73), peptide YY (PYY) 3-36 (74) , and PP (64), as well as neural signals derived from the gut consist of satiety systems. They influence the termination of individual meals and/or relate to the long-term regulation of body weight. Ghrelin administered into the periphery or cerebral ventricles potently stimulates food intake, leading to body weight gain in rodents (15, 16, (75) (76) (77) . The premeal increase of ghrelin may trigger the desire to eat in animals and humans.
GHRELIN ACTS ON NPY/AgRP NEURONS IN THE HYPOTHALAMUS
Ghrelin may represent a novel orexigenic pathway that centers on neuropeptide Y (NPY) and agouti-related peptide (AgRP), two potent orexigenic peptides in the hypothalamus (15, 16, (75) (76) (77) (Fig. 2) . Hypothalamic NPY is synthesized primarily in ARC neurons that project to adjacent hypothalamic areas such as the paraventricular nucleus (PVN), lateral hypothalamic area (LHA), and brainstem, major integration areas for the regulation of feeding behavior, energy expenditure, and gastrointestinal function (78 -80) . NPY is a powerful orexigenic neuropeptide. Chronic central NPY administration results in sustained hyperphagia, body weight gain, and a marked increase of body fat accumulation (81) . NPY promotes net energy gain by increasing food intake, decreasing energy expenditure, and exerting effects in peripheral tissues, including stimulation of glucocorticoid and insulin secretion, that favor further deposition of triglycerides in white adipose tissue.
AgRP was identified as a 132 amino acid peptide with 25% homology to the agouti protein that is a competitive antagonist of the melanocortin-1 receptor in hair follicles (79, 80) . The melanocortin system is unique in that it consists of agonists, melanocortins such as ␣-melanocyte-stimulating hormone (␣-MSH), and an endogenous antagonist, AgRP. By antagonism of the melanocortin-3 receptor and melanocortin-4 receptor, AgRP stimulates food intake and decreases energy expenditure. In the brain, AgRP is synthesized exclusively in the ARC by neurons that project to adjacent hypothalamic areas such as the PVN and LHA. The demonstration that AgRP mRNA is abundantly colocalized with NPY identifies NPY/AgRP neurons as a unique subset capa-ble of increasing food intake via two mechanisms: by increasing orexigenic NPY signaling on the one hand and decreasing anorexigenic melanocortin signaling on the other (79, 82) .
Arcuate NPY/AgRP neurons appear to play an important role in energy homeostasis, transducing changes of body fat content into adaptive feeding responses that are communicated by leptin and insulin, two adipostatic hormones with their circulating levels generally proportional to energy stores in adipose tissue (79) . The ARC is strategically positioned to be in direct communication with peripheral signals because of the absence of blood-brain barrier (BBB). Thus, the NPY/AgRP system senses and respond to a wide variety of hormones and nutrients relevant to both short-and long-term aspects of the regulation of energy balance. Defective inhibition of NPY/AgPP neurons can have major consequences: hyperphagia, reducing energy expenditure, disturbances of glucose and lipid metabolism, and obesity (7, 9, 11, 78 -83) .
NPY/AgRP gene expression is up-regulated during periods of negative energy balance such as fasting and insulin-deficient diabetes, although the magnitude of the respective response may differ (79) . Leptin and insulin subserve overlapping functions as principal inhibitors of NPY/AgRP neurons; a decrease in inhibitory input from these adiposity signals activates NPY/ AgRP and induces hyperphagic responses. These responses are mediated in part by the two orexigenic peptide systems in the LHA: melanin-concentrating hormone (MCH) and orexin, and projections from the ARC NPY/AgRP synapse on the MCH-or orexin-producing neurons (6, 11, 84, 85) .
GHRELIN IS A MISSING LINK BETWEEN ENTERIC NUTRITION AND CENTRAL REGULATION OF ENERGY BALANCE AND GROWTH
The stimulatory action of ghrelin on food intake is mediated by the NPY/AgRP pathway, since blockade of NPY Y1 feeding receptors or immunoneutralization of AgRP attenuates ghrelin-induced feeding (16, 76, 77) . Consistent with this, the majority of NPY neurons in the arcuate nucleus express GHS receptor (86) , and ϳ50% of cells activated (that express c-Fos mRNA) after GHS administration contain NPY mRNA (87) . Peripherally administered ghrelin induces Fos specifically in the ARC, and ϳ90% of the Fos-positive neurons express NPY and coexisting AgRP (88, 89) . NPY and AgRP mRNA expression in the ARC are increased after ghrelin administration to fed rats (16, 76, 77, 90) . The orexigenic activity of ghrelin is consistent with findings reported earlier showing that central administration of GHSs such as GHRP-6 and KP102 stimulates food intake and weight gain in rats (91) (92) (93) (94) . Chronic GHRP-2 treatment stimulates the accumulation of adipose tissue mass in NPY-deficient mice as in controls, paralleled by an increase of hypothalamic AgRP mRNA expression (95) . Central GHSs also activate Orexin (but not MCH) neurons, and ghrelin-induced feeding is attenuated by pretreatment with anti-orexin (but not anti-MCH) IgGs or in orexin knockout mice, indicating that ghrelin may selectively activate certain orexigenic pathway from NPY/AgRP to orexin (6, 11, 96, 97) .
The ability to delete a gene of interest in a tissuespecific manner is a considerable advantage in studying Orexigenic and adipogenic ghrelin is produced by and released from the stomach in response to fasting and hypoglycemia. Ghrelin and leptin regulate gastric motility, appetite, and body weight by counter-regulating the same hypothalamic signals such as neuropeptide Y (NPY) and agoutirelated peptide (AGRP), the two extraordinarily potent orexigenic peptides that simultaneously decrease energy expenditure. NPY and AGRP are coproduced in the arcuate nucleus (ARC) and act in the paraventricular nucleus (PVN) and adjacent hypothalamic areas such as the lateral hypothalamic area (LHA) in which orexin neurons exist. The NPY/ AgRP neurons transduce changes of body fat contents (as communicated by leptin and insulin) into adaptive feeding responses. Ghrelin is a novel neuroendocrine peptide that links the gastrointestinal system and the hypothalamic orexigenic pathway. Other gastrointestinal peptides such as glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) -8, peptide YY (PYY)3-36 and pancreatic polypeptide (PP) produces satiety through endocrine and/or neural pathways. Plus signs denote stimulatory input, and minus signs inhibitory input. Positive and negative regulators of body adiposity are shown as red and blue, respectively. VMH, ventromedial hypothalamus; DVC, dorsal vagal complex.
the function of the gene (8, 9) . Transgenic rats were recently created using an antisense GHS receptor mRNA under the control of the promoter for tyrosine hydroxylase to selectively attenuate GHS receptor protein expression in the ARC (98) . Transgenic rats have an expected phenotype with decreased food intake, lower body weight, and less adipose tissue; female rats show decreased GH secretion and plasma insulin-like growth factor-1 concentrations. This indicates the importance of ARC in ghrelin's action, also supported by experiments in rats treated neonatally with monosodium glutamate (MSG) (99) . MSG causes specific lesions in the ARC, resulting in a 70 -90% destruction of neuronal cell bodies including GHRH-, NPY-, and AgRP-containing neurons (99 -101) . In these rats, ghrelin shows a markedly diminished GH release and a failure to stimulate food intake. These results indicate that the primary site of action of ghrelin on appetite and GH release resides in the ARC, where circulating ghrelin is able to gain access (96, 102) . Although peripheral hormones such as leptin and insulin have been shown to cross the BBB by saturable and nonsaturable mechanisms (103, 104) , the transport process for ghrelin appears to be complex with only limited ability to penetrate into the brain areas within the BBB (105) .
The isolation of ghrelin from the stomach was thus a landmark finding not only in the GH field, but also in appetite and energy metabolism regulation (15-17, 60, 75-77) . During starvation, when leptin levels rapidly decline, circulating ghrelin levels increase, leading to the stimulation of NPY/AGRP production in the ARC (17) . Therefore, ghrelin and leptin are complementary, yet antagonistic, signals of the regulatory feedback loop that has developed to inform the brain about the current status of acute and chronic energy balance (Fig. 2) . Ghrelin is able to act on leptin-responsive arcuate neurons, the opposite effect of which may serve as a neurophysiological correlate of the orexigenic and anorexigenic effects of ghrelin and leptin (106 -108) . This view is supported by a recent finding that central leptin gene therapy blocks high-fat, diet-induced weight gain, hyperleptinemia, and hyperinsulinemia yet increases circulating ghrelin levels (109) . It is likely that the ghrelin and NPY/AgRP systems respond to fasting and negative energy balance at gastric and hypothalamic levels; ghrelin secretion may be more complex, responding to dietary manipulations, since stomach ghrelin cells are exposed to the luminal contents. The effects of GH in promoting the growth of soft tissue such as cartilage, together with the potent GHreleasing and orexigenic effect of ghrelin, indicate an involvement of the stomach in the regulation of growth processes (17, 76) .
Ghrelin's effect on body weight in rodents is due in part to altered metabolism and energy expenditure. Ghrelin reduces fat utilization and core body temperature in rats (15, 96) and reduces oxygen consumption in mice (16) . The brain controls energy expenditure via the sympathetic nervous system, which heavily innervates thermogenic tissues such as brown adipose tissue and skeletal muscle (110) . Ghrelin can reduce energy expenditure via NPY/AgRP pathway although the precise mechanism of the anabolic actions has yet to be fully characterized (16) . The brain also affects energy expenditure by means of the hypothalamicpituitary-thyroid axis. Ghrelin and other GHSs have been shown to decrease TSH levels and to stimulate the hypothalamic-pituitary-adrenal (HPA) axis, both resulting in an induction of a positive energy balance (111, 112) . Ghrelin may trigger increased release of GH and ACTH during fasting and be a key player connecting the nutritional state with endocrine changes. Leptin signals these endocrine axes in an opposite manner when a positive energy balance exists.
Ghrelin and leptin show antagonistic activity on gastrointestinal functions (16, 17) . Ghrelin increases gastric acid secretion, motility, and emptying (16, 113) whereas leptin decreases them. The gastro-prokinetic activity of ghrelin is independent of its GH-releasing effect and is likely to be mediated by the vagal-cholinergic muscarinic pathway (16, 37, 113) . Ghrelin is a potent gastro-prokinetic agent that accelerates the normal emptying process in rats and mice with doses compatible to those required to stimulate appetite and GH release (16, 114) . Ghrelin also accelerates the transit of the small intestine but not that of the colon. The 28 amino acid and the des [Gln 14 ]-27 amino acid octanoylated forms appear to be equally bioactive (114) . It was reported that calcitonin gene-related peptide (CGRP) 8-37, an antagonist of CGRP, is among the few agents with beneficial effects on the inhibition of gastric emptying after surgery (115) . Ghrelin is more active than CGRP 8-37 and is capable of reversing the postoperative gastric ileus in which motilin or motilin receptor agonist erythromycin is without effect (114) . Therefore, ghrelin may be the most potent drug tested to accelerate gastric emptying in rodents.
Plasma motilin concentrations are known to be highly variable during the interdigestive fasting period (34, 39, 116) . Periodic and recurrent increases in motilin are seen, which are synchronized with the migrating motor complex (MMC) of the fasting gastrointestinal tract. MMC is a recurrent pattern of cyclic occurring motor activity and can be divided into three distinct phases: phase I characterized by motor quiescence; phase II consisting of irregular motor activity; and phase III, a short burst of rhythmic contractions (37, (117) (118) (119) . In dogs and humans, the rises in circulating motilin regulate the appearance of the phase III contractions from the antroduodenal region to the distal gut (37, 42) . We recently examined the effect of ghrelin on the gastroduodenal motility in a freely moving conscious rat model that permits the measurement in the physiological fed and fasted states of the animals ( Fig. 3) (120, 121) . When ghrelin is administered into the lateral cerebral ventricle or the tail vein of fasted animals, it potentiates phase III-like contractions in the antrum and duodenum. When ghrelin is administered in fed animals, it disrupts the fed motor activity and induces phase III-like contractions despite the presence of food in the stomach. The delayed occurrence of fasted motor activity after intravenous ghrelin is due to the low intragastric pH, which is normally involved in the postprandial interruption of fasted motor activity (118, 122) . Vagal and nonvagal pathways may mediate these actions of ghrelin since vagotomy blocks the responses by central, but not peripheral, administration of ghrelin (114) . Vagotomy is reported not to block the inhibition of pancreatic protein secretion by ghrelin, which may be exerted at the level of intrapancreatic neurons (123) .
Previous studies demonstrated that food intake and gastrointestinal fed and fasted motor activities are closely related (124, 125) . NPY not only induces food intake in fed animals but also changes gastroduodenal motor activity from fed to fasted pattern (Fig. 3) (120) . This motor effect of NPY is mediated by the Y2 receptor rather than the Y1 and Y5 receptors, which mediate appetite stimulation by the peptide (78) . Administration of anti-NPY antiserum into the cerebral ventricle abolishes the fasted motor activity and induces fed-like contractions, indicating an involvement of the endogenous NPY and Y2 receptor system in the generation of fasted motor activity (120) . AgRP is also able to induce fasted motor activity in fed animals (unpublished data). Therefore, the interdigestive phasic contraction can be correlated well with the onset of hunger sensation and initiation of feeding. On the other hand, urocortin, a potent anorexigenic peptide belonging to corticotropinreleasing factor (CRF) family, induces fed-like motor activity when administered centrally or peripherally in fasted animals (126) . CCK is another example that suppresses feeding and MMC following either route of administration (127) (128) (129) . The finding that the gastroduodenal motor effect of ghrelin is blocked not only by the GHS receptor antagonist [D-Lys3] GHRP-6, but also by immunoneutralization of NPY in the brain, indicates that NPY neurons mediates this effect under the presence of the vagus nerve (Fig. 3) (121) . Since ghrelin antagonist/ antiserum treatment reduces body adiposity and gastric emptying, ghrelin may be critically involved in these alterations (17, 65) (Fig. 2) .
It is reported that NPY and Y2 agonist inhibit gastric emptying of solid or liquid meals (130) and a Y2 agonist applied to the dorsal vagal complex suppresses thyrotropin-releasing hormone (TRH) -stimulated gastric motility (131) . Since the ghrelin-NPY pathway is downregulated after feeding, it is not known whether it plays an important role in postprandial gastrointestinal physiology. It is generally agreed that motilin's physiological effect is limited to the interdigestive state (132) . Although PYY3-36 is a physiological satiety factor acting on the NPY Y2 receptor in the ARC, it does not affect gastric emptying (74) .
Although peripherally administered ghrelin has no effect on gastric acid secretion in pylorus-ligated conscious rats, central ghrelin produces a long-lasting gastric inhibitory action (133) (though stimulatory under anesthesia; 134, 135) . Distinct pathways may be involved in gastric and feeding activities, since EP40737, a hexapeptide that stimulates GH release but is devoid of effects on feeding (136) , is able to reduce gastric acid secretion (133) . It remains to be determined whether a small amount of ghrelin produced in the hypothalamus (which hardly contributes to circulating ghrelin) (62) is physiologically relevant and involved in the regulatory feedback loop (Fig. 2) . Ghrelin-like immunoreactive neurons are observed in the ventral part of the ARC (137) or the internuclear space between the PVN, ARC, VMH, and DMH (108) . The axons of hypothalamic ghrelin neurons abut NPY axons presynaptically in the ARC and PVN and may increase secretion of GABA, NPY, and AgRP (108).
THE STOMACH IS AN IMPORTANT COMPONENT OF ENERGY HOMEOSTASIS EQUATION
Gastric emptying plays an important role in regulating food intake (120, 124, 126, 138 -146) . Gastric distension acts as a satiety signal to inhibit food intake, and rapid gastric emptying is closely related to overeating and obesity (139, 140) . Lesions of the ventromedial nucleus (VMH) of the hypothalamus are known to disrupt autonomic output controlling the stomach and increase the normally slow daylight rate of gastric emptying of regular diet (140) . The abbreviated satiating effect of food resulting in such gastric acceleration is thought to be a major cause in the obese VMH syndrome, along with other autonomic defects such as insulin hypersecretion and reductions in fat mobilization and thermogenic capacity (5, 7, 9) .
Most anorexigenic molecules such as CCK, CRF, and IL-1 not only suppress feeding but also decrease gastric transit1 (24, 126, 139, (141) (142) (143) (144) (145) (146) (147) . The inhibitory effect of peripherally administered CCK-8 on the rate of gastric emptying has been shown to contribute to its ability to inhibit food intake in various species (16, 138, 148 -151) . The inhibitory effects on gastric emptying by CRF, CRF type2 receptor agonist urocortin, and their analogs paralleled the inhibitory effects on food intake (139) . The ob/ob mice are another example that shows rapid gastric emptying and overeating at the development of obesity (1, 6, 16, 139) . Urocortin potently decreased food intake and reversed rapid gastric emptying in the animals (139) . Repeated administration of urocortin decreased body weight and improved glycemic control, indicating that the decreased absorption rate of nutrients is beneficial not only to decrease food intake but also to decrease the requirements of insulin in obese diabetic animals. GLP-1 or its potent analogs may be effective in treating such diabetic animal models and humans (73, 152) although they may affect sympathetic outflow (153) .
Recently leptin and its receptor were identified in gastric mucosa in animals (154, 155) and humans (156, 157) (Fig. 2) . Gastric leptin can be released into the blood and gastric juice after feeding, insulin-induced hypoglycemia, or infusion of CCK-8, pentagastrin, and secretin, providing evidence that leptin is a stomachderived protein (154, 156, 157) . Gastric leptin may have a role in appetite regulation by acting directly in the hypothalamus or in synergy with CCK via the vagal pathway (72, (157) (158) (159) or by modifying absorption of dietary protein and fats (160) . How leptin interacts with ghrelin in the stomach needs to be determined. However, the existence of a regulatory feedback loop involving the stomach suggests a fascinating role of ghrelin and leptin as an interface between regulatory centers in the brain of nutritional intake, gastrointestinal function, metabolic control, and growth regulation.
Enterostatin may be another component of this system, formed through the processing of pancreatic procolipase, a protein necessary for intestinal fat digestion (161) . It is also produced in chief cells of the stomach as part of procolipase as well as in enterochromaffine cells independent of procolipase, most frequently in the antral part of the stomach extending all along the intestine down to the ileum (162) . Enterostatin increases during fat feeding, where it is found in circulating blood as well as in intestinal lumen and the lymph. When reducing food intake by either peripheral or central administration, enterostatin behaves as a physiological satiety substance, inducing early satiety (163) . During long-term treatment, enterostatin is able to reduce body weight in rodents when fed a high-fat diet. A reduced body weight may be explained by a decreased food intake involving delayed gastric emptying (164) and an increased energy expenditure through activation of the sympathetic nervous system and increased expression of uncoupling protein 1 in brown adipose tissue. The mechanism of action for restriction of fat intake may involve serotonin, opioids and dopamine, which are components of the reward system (161) . A more complete understanding of how the stomach regulates energy balance and other brain functions thus depends upon the elucidation of the gastric machinery and network of which molecules like ghrelin, leptin, and enterostatin are a part.
VAGAL AFFERENT NEURONS ARE AN IMPORTANT TARGET FOR PEPTIDE ACTIONS
At least part of ghrelin and leptin signaling from the stomach is mediated by an ascending neural network through the vagus nerve and brainstem nuclei that ultimately reaches the hypothalamus (16, 158, 165) . Abdominal vagal afferents have their cell bodies in the nodose ganglion. Neurotransmitters and receptors synthesized within the ganglion and subsequently transported to the nerve terminals are being identified (166) . The presence of leptin within the gut, the discovery of the leptin receptor on the vagus nerve, the modulatory effects of leptin on intestinal vagal mechanoreceptors, and the known involvement of the vagus and other afferents in transmitting satiety all suggest a need to evaluate the potential of other feeding regulatory hormones located within the hypothalamus and/or gut on vagal nerve function (166 -170) .
Orexins may be another example, produced in neurons and endocrine cells in the gut (171) in addition to neurons in the LHA. A recent study localized the orexin-1 receptors to vagal afferent neurons that also expressed CCK-1 (A) and leptin receptors and showed that orexin-A inhibited the response of afferent nerve fibers to CCK (172) . The mechanism by which CCK signals to the brain on satiety is known to include activation of CCK-1(A) receptors produced in vagal afferent cell soma and transported peripherally (173) (174) (175) . The dual CCK-leptin signals are transmitted to the nucleus tractus solitarius, then hypothalamic sites, of which the PVN appears to be the primary target, orchestrating appropriate food intake alterations (159) .
Ghrelin receptors are also synthesized in vagal afferent cell soma and intravenous ghrelin suppresses firing of the vagal afferents (16, 165) . Selective chemical blockade by capsaicin or surgical deafferentation of the gastric vagal nerve blocks the Fos expression in the ARC and the feeding response to peripherally administered ghrelin. The finding that vagotomy eliminates the GH response to ghrelin indicates a novel vagus-mediated GH secretion pathway (165) in addition to the known vagus-mediated regulation of gastrointestinal motility and secretion, behavioral responses such as satiety, and pathophysiological sensations and reflexes such as nausea and vomiting (166) . These data stress the importance of the vagus nerve in conveying ghrelin signals to the brain although the extent of the dependence needs to be further examined.
CLINICAL IMPLICATIONS GH deficiency
Data have shown that the combined administration of GHRH and GHSs appears to be the most potent stimulus of GH release in humans (24, 176, 177) . It may be a convenient, safe, and reliable test for the diagnosis of GH deficiency. Administration of GHS is preferable to direct administration of GH because it induces a more physiological profile of GH secretion, not bypassing the feedback loop controlling the GH-IGF-1 axis (178) . Potential targets for GHS compounds include children (179) and adults with GH deficiency associated with alterations in body composition, increased prevalence of cardiovascular morbidity, and shortened life expectancy (180, 181) . The majority of GH-deficient subjects respond to GHS, which can be administered intravenously, intramuscularly, subcutaneously, orally, intranasally, or transdermally (17, 19, 182) . GHS analogs could be used in all pathophysiological states where the administration of moderate GH doses has been shown to be effective such as aging, catabolic states, and osteoporosis. Although ghrelin levels in GH-deficient subjects are not significantly different from controls (183) , it remains to be seen whether some subjects can lack ghrelin and have growth-retarded phenotype and whether the ectopic production of ghrelin can lead to acromegaly (23) . Ghrelin has been shown to regulate expression of a pituitary-specific transcription factor, Pit-1, suggesting a role in somatotroph differentiation in addition to GH secretion (184) . Transgenic animals that overexpress or delete the ghrelin gene may help address these issues.
Obesity
Obesity is characterized by a blunted GH secretion that might help to maintain this state and is reversed by weight loss (24, 185) . Fasting plasma ghrelin concentrations in obesity are significantly lower and are negatively correlated with body mass index, percent body fat, and/or fasting insulin and leptin concentrations (180, 187) . The low levels of ghrelin might contribute to the decreased GH secretion in obese patients. Plasma ghrelin levels are also negatively correlated with plasminogen activator 1 (PAI-1) levels that are elevated in insulin-resistant subjects and associated with increased cardiovascular risk of atherothrombosis (188) . The decreased ghrelin secretion in established obesity may be a physiological adaptation to long-term positive energy balance although a particular subset of obesity may be associated with high levels of ghrelin (189) . Despite its low levels, ghrelin may act to maintain the increased body weight as with NPY (190, 191) , since weight loss increases ghrelin levels that are correlated with the extent of weight loss (189) . The lack of suppression of plasma ghrelin after a meal in obese subjects may contribute to increased food consumption (192) .
A recent study suggests that ghrelin is a long-term regulator of body weight rather than a short-term, meal-related orexigenic signal in humans (193) . Gastric bypass surgery is an important treatment for morbid obesity that can produce prolonged weight reduction (194) . Gastric bypass subjects exhibit markedly different ghrelin secretary profiles, with markedly reduced cumulative secretion as well as loss of premeal increase or diurnal variability that normally peaks between 12 and 2 am and nadirs at 9 -10 am. Conversely, bypass subjects exhibit normal postprandial insulin secretion and diurnal leptin cycling. Therefore, suppression of plasma ghrelin by gastric bypass surgery can contribute to the efficacy of this procedure as weight reduction therapy in addition to the physical restriction of the stomach (gastric pouch) and the reduction of nutrient digestion and absorption (long Roux-en-Y) (195) .
Prader-Willi syndrome is the most common form of human syndromic obesity, occurring in 1 of 10,000 -16,000 live births (196 -198) . It is characterized by severe hyperphagia, GH deficiency, hypogonadism, neonatal hypotonia, dysmorphic features and cognitive impairment. Although Prader-Willi syndrome arises from functional loss of several paternally expressed genes in an imprinted domain on chromosome 15, mediators of the phenotype are not well known (9, 196) . Recent studies demonstrated that while obesity per se is associated with low ghrelin levels, that accompanied by Prader-Willi syndrome is associated with elevated ghrelin with no decrease after a meal (197, 198) . The increased ghrelin levels are comparable to or higher than those reported to stimulate appetite and food intake during exogenous ghrelin administration in humans (199) , suggesting a role of ghrelin in the pathogenesis of hyperphagia in Prader-Willi syndrome. It remains to be determined whether elevated ghrelin participates in the GH deficiency by such mechanisms as paradoxical override inhibition described in continuous GHRH stimulation of GH (197, 200) . Interventions that lower plasma ghrelin levels or antagonize its orexigenic effects warrant consideration in treatment of this type of obesity. Gastric bypass may have less efficacy in Prader-Willi patients than in other obese children and adolescents (201, 202) . Ghrelin levels are low or normal in patients with other genetic obesity such as those with leptin receptor mutation or melanocortin 4 receptor mutation (197) .
Rapid gastric emptying may have a role in apparent leptin resistance since the gastromotor abnormality is quantitatively the most important precondition of excess fat deposition and the hyperphagic pattern of frequent meals in some animal models of obesity (140) . Rapid gastric emptying has been reported in clinically obese populations, and the appetite suppressant, antiobesity agent fenfluramine (although withdrawn from the global market due to the unfortunate development of valvuloplasty) (10, 203) may reduce food intake by slowing gastric emptying and so extending the satiating effect of a meal (140, 204, 205) . Gastric emptying half-time as assessed by 13 C-octanoic acid breath test is correlated with fasting plasma ghrelin levels in healthy humans, though this could be interpreted as a physiological reaction to balance of gastric motor function (206) . A failure to demonstrate the prokinetic effect of a physiological dose of exogenous ghrelin is reported when gastric emptying is measured using the paracetamol absorption test (199) . More studies, especially those using radionuclide techniques (207) , are needed to evaluate the actions of ghrelin/GHS on gastric emptying in humans. It remains to be examined whether ghrelin/GHS antagonist is effective in slowing abnormal gastric emptying and ameliorating excessive food intake and fat deposition in humans as it does in animals (61).
Gastrointestinal disorders
The beneficial effect of ghrelin in an animal ileus model (107) is interesting. Abdominal surgery inhibits gastric emptying and digestive motor activity in experimental animals and humans (114, 208, 209) . Abdominal surgery with manipulation of viscera induces postoperatively a state of digestive motor inactivity that may occasionally be overly prolonged while associated with significant morbidity; these patients could certainly benefit from a specific and effective treatment. Attempts by various prokinetics such as acetylcholine, cisapride, and motilide to stimulate directly or via the afferent neural pathways frequently gave disappointing results (208 -210) . However, ghrelin is the most potent drug to reverse postoperative gastric ileus in the animal model (114) . It should be examined whether ghrelin or GHS compounds could help prevent postoperative gastric ileus in humans.
Gastroparesis is associated with many diseases, the most frequent cause of which is diabetes mellitus. About one-half of patients with insulin-dependent or non-insulin-dependent diabetes have delayed gastric emptying. Diabetic gastroparesis is generally ascribed as a consequence of autonomic neuropathy although hyperglycemia per se may contribute to the pathogenesis of disordered gastric motility (211). Motilin and erythromycin are able to accelerate gastric emptying in such patients probably by direct effects on smooth muscles (132, 207, 212, 213) . Due to the potent prokinetic activity in animals, ghrelin and GHS compounds may also offer therapeutic potentials to treat the disorder.
Short bowel syndrome is a condition that occurs after resection of a substantial portion of small intestine and is characterized by malnutrition. The malnourished patients have lower plasma ghrelin concentrations in contrast to the expected increase (214) . This indicates that significant amounts of ghrelin are produced by neuroendocrine cells in the intestine and the decrease in plasma ghrelin levels may contribute to decreased appetite in these patients. It is possible that the short bowel feeds back on the release of ghrelin.
Helicobacter pylori is known to modify leptin expression in the gastric mucosa (215) . After eradication of H. pylori, median and integrated plasma ghrelin is increased significantly, making it likely that the association of H. pylori and appetite is mediated in part through ghrelin. Although there are no studies in adults illustrating whether H. pylori-positive subjects have a lower body weight than negative controls, H. pylori children may have a high incidence of growth retardation (216 -221) , as demonstrated in experimental animals (222) .
A recent study indicates a potent protective effect against ethanol-induced gastric lesions by central ghrelin and a partial peripheral protective effect (223) . This effect of ghrelin is mediated by endogenous nitric oxide (NO) release and requires the integrity of sensory nerve fibers. Since acute hemorrhagic and erosive gastropathy may represent a potentially life-threatening condition, ghrelin may deserve attention as a new pharmacological tool for the treatment.
Cachexia
Recent studies suggest that ghrelin may be a clinical marker of catabolism (17) . Elevated levels of circulating ghrelin are observed in cachexia associated with chronic heart failure (224) or liver cirrhosis. Indeed, GHSs such as MK-0677 and GHRP-2 are reported to reverse diet-induced catabolism and to improve alterations in the somatotrophic axis and protein catabolism in patients with prolonged, severe illnesses (24, 225, 226) .
GH has been used as a potential anabolic agent to counteract muscle wasting associated with surgical stress, sepsis, glucocorticoid administration, AIDS, and cancer (227, 228) . GH stimulates whole body and muscle protein synthesis under some conditions. Ghrelin or ghrelin/GHS compounds may improve the treatment of such patients, especially aging patients in whom reduced GH secretion, reduced muscle mass, and anorexia are often observed (227) . The age-related decline of plasma ghrelin may explain in par, the somatotrophic dysregulation and anorexia of elderly subjects (229) . Chronic treatment of elderly with MK-0677 is reported to reverse age-related changes of the GH/IGF-1 axis and to improve the quality of sleep in healthy elderly subjects (25, 230) .
The impressive orexigenic effect of ghrelin administered peripherally in rodents indicates it warrants evaluation in treating conditions associated with excessive weight loss such as cancer. Weight loss is a potent stimulus to food intake in normal humans and animals. Therefore, the persistence of anorexia in cancer implies a failure of this adaptive feeding response (147, 231) . Cytokines, proposed mediators of the cachectic process, may play a pivotal role in long-term inhibition of feeding by mimicking the hypothalamic effect of excess negative feedback signaling from leptin (147, 231) . IL-␤, a cytokine known to be elevated in malignancy (147, 232) , decreases not only hypothalamic NPY mRNA expression but also gastric ghrelin mRNA expression, and peripherally administered ghrelin reverses the IL-1␤-induced loss of appetite and body weight (16, 233) .
It is known that NPY feeding systems are dysfunctional in such wasting models as tumor-bearing animals (147, 231, 234 -240) . NPY biosynthesis in the ARC may be elevated in animal models of cachexia, consistent with an adaptive response (240, 241) . However, NPY release in the hypothalamus or the orexigenic potency of NPY is markedly attenuated compared with the controls (240, 241) . As with NPY, plasma concentrations of ghrelin may be increased in some animal models of cachexia, and ghrelin may display markedly blunted orexigenic potency (241) although its therapeutic efficacy may depend on the animal model used. Ghrelin is reported to be elevated in cachectic patients with lung cancer and anorectic patients after chemotherapy (242) . Since orally bioavailable GHSs with longer lasting potency have been developed and administered safely to humans, it remains to be determined whether these compounds may have an effect in the treatment of cancer anorexia-cachexia syndrome, except for ghrelin-responsive malignancy. Treatment options for cancer anorexia are few; the progesteronelike hormone megestrol acetate is the most extensively characterized agent in animals and humans, which acts through NPY to increase food intake and body weight (232, 243) .
The gastro-prokinetic activity may be beneficial since most of the wasting conditions are associated with delayed gastric emptying (124, 147) . Erythromycin has been shown to accelerate delayed gastric emptying associated with cancer therapy and other critical conditions (37, 246) .
Eating disorders
Anorexia nervosa is a psychopathologic disorder that presents with neuroendocrine alterations reflecting starvation (245) . Patients experience hunger, but are prevented from eating by intense fear of losing control over eating and becoming overweight. Plasma ghrelin concentrations in patients with anorexia nervosa are significantly elevated compared with those of healthy controls, although there may be some patients with normal (not increased) ghrelin levels (186, 221, 229, 246) . Plasma ghrelin levels do not fall after food intake, suggesting that a single meal is not sufficient to suppress the drive to eat in the subjects (247) . NPY concentrations in the cerebrospinal fluid are also increased in anorexia nervosa (245, 248) . Ghrelin levels return to normal after partial weight recovery, suggesting it reflects a physiological effect to compensate lack of nutritional intake and energy stores (249) . Whether this reflects a state of ghrelin resistance analogous to the model of leptin resistance is not known (249) . The increased ghrelin might explain relatively high plasma concentrations of growth hormone in anorexic patients. Although there may be no difference in ghrelin secretion between restrictive vs. bulimic anorexia nervosa (246) , plasma ghrelin is significantly elevated in patients with bulimia nervosa (250) , suggesting that abnormal eating behaviors with habitual binge eating and purging may influence ghrelin secretion. It remains to be examined whether binges in bulimia nervosa are the consequence of elevated ghrelin.
Others
Hyperphagia and altered fuel metabolism are prominent features of uncontrolled diabetes mellitus in both animals and humans (251) . In an insulin-deficient diabetes model induced by the ␤ cell toxin streptozotocin, plasma ghrelin concentrations are significantly elevated with a concomitant decrease in plasma leptin and an increase in hypothalamic NPY gene expression (252) . All of these changes are reversed by insulin treatment. The increased food intake seen in the animal model is partially reversed by administration of a ghrelin receptor antagonist [D-Lys-3]-GHRP-6, suggesting that increased ghrelin together with decreased leptin causes hyperphagia via the NPY (252, 253) and AgRP (251) pathway. Although there may be no significant difference in basal plasma ghrelin concentrations between healthy subjects and type 2 diabetics (186), the pathophysiological significance of ghrelin in diabetic hyperphagia that makes it difficult for patients to adhere to diet therapies should be examined in uncontrolled diabetics.
Ghrelin and GHS-RIa are present in endocrine pancreas (254) . Ghrelin produces significant hyperglycemia, which is followed by a reduction in insulin secretion in humans (254) . Coupled with the observation that chronic treatment with MK-0677 induces hyperglycemia (albeit with hyperinsulinemia) in elderly subjects (255) , this evidence indicates that ghrelin may play a role in glucose metabolism.
Ghrelin cells are detected in human fetal stomach (50) as well as intestine, pancreas (56) , and lung (256) long before ECL and chief cells of the stomach, the latter of which are a major source of leptin (154) . The early and widespread development of ghrelin cells in embryonic tissues may indicate an important role for fetal ghrelin either in promoting body growth through stimulation of GH release or by fulfilling some local trophic and morphogenetic role (50, 56, 256, 257) . Ghrelin is present in the placenta, where all the main regulatory components (GH, GHRH, IGF-1, and somatostatin) appear to be involved in fetal growth in animals and humans. Higher levels of circulating ghrelin and lower reductions after intravenous glucose are seen in infants born small for gestational age who show greater infancy weight gain and catch-up growth (258) .
Ghrelin may have beneficial hemodynamic effects in humans via reducing cardiac afterload and increasing cardiac output without increasing heart rate (259) . Ghrelin may cause inhibition of growth in breast cancer (260) , thyroid cancer (261) , and lung cancer (262) cell lines, which are independent of the GH-releasing effect. In contrast, ghrelin may induce a proliferative response in cell lines of hepatoma (263) and those of prostate cancer in which IGF-1 and GH may have tumorigenic potential (264) . Since both ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells, acylation of the peptide is needed for endocrine actions (42) . These findings indicate the existence of additional receptor subtypes that may exhibit different affinities for ghrelin/GHS and different pathophysiological relevance (42, 254, 262, 265) .
Ghrelin expression is reported in gastrointestinal and pancreatic endocrine tumors and gastric neuroendocrine cell hyperplasia (53, 266) . Ghrelin-producing endocrine tumors may help in better understanding ghrelin functions in humans and screening of circulating ghrelin levels for diagnostic work-up. Ghrelin may also directly stimulate the differentiation of preadipocytes and inhibit lipolysis, suggesting a role in the process of adipogenesis (267) . Ghrelin may increase anxiety-like behavior and memory retention in rodents (268, 269) and may be a sleep-promoting factor in humans (270) . Since the GHS receptor(s) is widely distributed in the body, many other physiological effects of ghrelin may remain to be uncovered.
PERSPECTIVE
Ghrelin has illustrated the importance of functional interdependency of the stomach and hypothalamus, providing a crucial missing link in the regulation of energy balance, growth, and the coordinated gastrointestinal function. The arcuate NPY/AgRP neurons may act to sense and respond to a wide variety of hormone and nutrient signals in the blood that are relevant to both short-and long-term aspects of energy homeostasis Eq. (7, 9, 11, 80) (Fig. 2) . These diverse signals are integrated and transmitted to motor centers such as PVN, LHA, and brainstem to produce the coordinated actions on feeding and associated autonomic, neuroendocrine, and gastrointestinal activities. Ghrelin may be a counterpart to leptin and a key afferent component in this system. Vagal pathways are deeply involved in these diverse actions of ghrelin and other gastrointestinal peptides.
Characterization of the gene encoding ghrelin and its overall genomic structure has enabled genomic screening of the ghrelin gene. Recent studies suggest that Arg5lGln or Leu72Met polymorphism of preproghrelin gene may be associated with lower plasma ghrelin and insulin resistance or lower fat accumulation (271, 272) . However, Leu72Met polymorphism may be associated with obesity in children and may modulate glucose-induced insulin secretion (273, 274) . The finding that plasma ghrelin concentrations at baseline are more alike within pairs of twins than between pairs indicates a probable genetic effect underlying the variability in plasma ghrelin levels (275) . Further studies are warranted to examine whether genetic variation at ghrelin or its receptor locus could be a genetic factor determining fat accumulation and statural growth.
In the next few years, we foresee a rapid increase of knowledge in such basic mechanisms in healthy and diseased subjects, as well as in the diagnostic and therapeutic uses of natural (ghrelin) and artificial GHSs. It will become apparent whether ghrelin is the sole ligand or one of a number of ligands activating the GHS receptor and whether GHS-RIa is the sole receptor or one of a group of receptors for such ligands.
The discovery of ghrelin and approaches designed to modulate the gastric neuroendocrine system open new fascinating perspectives of research and therapeutic potential on gastrointestinal, metabolic, endocrine, and other various diseases.
